Renal complications in transfusion-dependent beta thalassaemia

Blood Reviews

Volumn 24, Issue 6, 2010, Pages 239-244

  Ponticelli, Claudio ^a   Musallam, Khaled M ^b   Cianciulli, Paolo ^c   Cappellini, Maria Domenica ^d  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

^c S EUGENIO HOSPITAL   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

Author keywords

Anaemia; Iron chelation; Iron overload; Kidney; Thalassaemia major

Indexed keywords

ACETYLGLUCOSAMINIDASE; BETA 2 MICROGLOBULIN; DEFERASIROX; DEFEROXAMINE; FERRITIN; HEMOSIDERIN; IRON CHELATING AGENT;

ACUTE KIDNEY FAILURE; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CAUSAL ATTRIBUTION; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FERRITIN BLOOD LEVEL; FUNCTIONAL ASSESSMENT; GLOMERULAR HYPERFILTRATION; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION RATE; HUMAN; IRON BLOOD LEVEL; IRON OVERLOAD; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY PLASMA FLOW; LIPID PEROXIDATION; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN URINE LEVEL; PROTEINURIA; RETICULOCYTE COUNT; SICKLE CELL ANEMIA; SIDE EFFECT; THALASSEMIA MAJOR; TUBULAR DYSFUNCTION; URINARY EXCRETION;

BETA-THALASSEMIA; BLOOD TRANSFUSION; HUMANS; IRON OVERLOAD; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS;

EID: 78149467188     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.08.004     Document Type: Article

References (59)

1. Weatherall D.J., Clegg J.B. The thalassaemia syndromes 2001, Blackwell Science, Oxford ; Malden, MA. 4th ed.
2. Taher A.T., Musallam K.M., Inati A. Iron overload: consequences, assessment, and monitoring. Hemoglobin 2009, 33(Suppl 1):S46-S57.
3. Borgna-Pignatti C., Rugolotto S., De Stefano P., Zhao H., Cappellini M.D., Del Vecchio G.C., et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004, 89:1187-1193.
4. Michelakakis H., Dimitriou E., Georgakis H., Karabatsos F., Fragodimitri C., Saraphidou J., et al. Iron overload and urinary lysosomal enzyme levels in beta-thalassaemia major. Eur J Pediatr 1997, 156:602-604.
5. Sumboonnanonda A., Malasit P., Tanphaichitr V.S., Ong-ajyooth S., Sunthornchart S., Pattanakitsakul S., et al. Renal tubular function in beta-thalassemia. Pediatr Nephrol 1998, 12:280-283.
6. Ong-ajyooth L., Malasit P., Ong-ajyooth S., Fucharoen S., Pootrakul P., Vasuvattakul S., et al. Renal function in adult beta-thalassemia/Hb E disease. Nephron 1998, 78:156-161.
7. Aldudak B., Karabay Bayazit A., Noyan A., Ozel A., Anarat A., Sasmaz I., et al. Renal function in pediatric patients with beta-thalassemia major. Pediatr Nephrol 2000, 15:109-112.
8. Koliakos G., Papachristou F., Koussi A., Perifanis V., Tsatra I., Souliou E., et al. Urine biochemical markers of early renal dysfunction are associated with iron overload in beta-thalassaemia. Clin Lab Haematol 2003, 25:105-109.
9. Smolkin V., Halevy R., Levin C., Mines M., Sakran W., Ilia K., et al. Renal function in children with beta-thalassemia major and thalassemia intermedia. Pediatr Nephrol 2008, 23:1847-1851.
10. Economou M., Printza N., Teli A., Tzimouli V., Tsatra I., Papachristou F., et al. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Acta Haematol 2010, 123:148-152.
11. Sadeghi-Bojd S., Hashemi M., Karimi M. Renal tubular function in patients with beta-thalassaemia major in Zahedan, southeast Iran. Singapore Med J 2008, 49:410-412.
12. Sumboonnanonda A., Sanpakit K., Piyaphanee N. Renal tubule function in beta-thalassemia after hematopoietic stem cell transplantation. Pediatr Nephrol 2009, 24:183-187.
13. Zhou X.J., Laszik Z., Wang X.Q., Silva F.G., Vaziri N.D. Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 2000, 80:1905-1914.
14. Landing B.H., Gonick H.C., Nadorra R.L., Hyman C.B., Wells T.R., Villarreal-Engelhardt G., et al. Renal lesions and clinical findings in thalassemia major and other chronic anemias with hemosiderosis. Pediatr Pathol 1989, 9:479-500.
15. Kassab-Chekir A., Laradi S., Ferchichi S., Haj Khelil A., Feki M., Amri F., et al. Oxidant, antioxidant status and metabolic data in patients with beta-thalassemia. Clin Chim Acta 2003, 338:79-86.
16. King S.M., Donangelo C.M., Knutson M.D., Walter P.B., Ames B.N., Viteri F.E., et al. Daily supplementation with iron increases lipid peroxidation in young women with low iron stores. Exp Biol Med (Maywood) 2008, 233:701-707.
17. Kokoszko A., Dabrowski J., Lewinski A., Karbownik-Lewinska M. Protective effects of GH and IGF-I against iron-induced lipid peroxidation in vivo. Exp Toxicol Pathol 2008, 60:453-458.
18. Zager R.A., Johnson A.C., Hanson S.Y. Parenteral iron nephrotoxicity: potential mechanisms and consequences. Kidney Int 2004, 66:144-156.
19. Zager R.A., Johnson A.C., Hanson S.Y. Proximal tubular cytochrome c efflux: determinant, and potential marker, of mitochondrial injury. Kidney Int 2004, 65:2123-2134.
20. Fibach E., Rachmilewitz E. The role of oxidative stress in hemolytic anemia. Curr Mol Med 2008, 8:609-619.
21. Nagababu E., Gulyani S., Earley C.J., Cutler R.G., Mattson M.P., Rifkind J.M. Iron-deficiency anaemia enhances red blood cell oxidative stress. Free Radic Res 2008, 42:824-829.
22. Du W., Adam Z., Rani R., Zhang X., Pang Q. Oxidative stress in Fanconi anemia hematopoiesis and disease progression. Antioxid Redox Signal 2008, 10:1909-1921.
23. Kaissling B., Spiess S., Rinne B., Le Hir M. Effects of anemia on morphology of rat renal cortex. Am J Physiol 1993, 264:F608-F617.
24. Mastrangelo F., Lopez T., Rizzelli S., Manisco G., Corliano C., Alfonso L. Function of the kidney in adult patients with Cooley's disease. A preliminary report. Nephron 1975, 14:229-236.
25. Koren G., Kochavi-Atiya Y., Bentur Y., Olivieri N.F. The effects of subcutaneous deferoxamine administration on renal function in thalassemia major. Int J Hematol 1991, 54:371-375.
26. Bruck E. Renal function in anemia. AMA Am J Dis Child 1953, 86:511-512.
27. Davis L.E., Hohimer A.R. Hemodynamics and organ blood flow in fetal sheep subjected to chronic anemia. Am J Physiol 1991, 261:R1542-R1548.
28. Haymann J.P., Stankovic K., Levy P., Avellino V., Tharaux P.L., Letavernier E., et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associated feature. Clin J Am Soc Nephrol 2010, 5:756-761.
29. Lafferty H.M., Anderson S., Brenner B.M. Anemia: a potent modulator of renal hemodynamics in models of progressive renal disease. Am J Kidney Dis 1991, 17:2-7.
30. Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol 2006, 17:17-25.
31. Alfrey A.C. Role of iron and oxygen radicals in the progression of chronic renal failure. Am J Kidney Dis 1994, 23:183-187.
32. Ali D., Mehran K., Moghaddam A.G. Comparative evaluation of renal findings in Beta-thalassemia major and intermedia. Saudi J Kidney Dis Transpl 2008, 19:206-209.
33. Papassotiriou I., Margeli A., Hantzi E., Delaporta P., Sergounioti A., Goussetis E., et al. Cystatin C levels in patients with beta-thalassemia during deferasirox treatment. Blood Cells Mol Dis 2010, 44:152-155.
34. Naicker S., Fabian J., Naidoo S., Wadee S., Paget G., Goetsch S. Infection and glomerulonephritis. Semin Immunopathol 2007, 29:397-414.
35. Francoz C., Glotz D., Moreau R., Durand F. The evaluation of renal function and disease in patients with cirrhosis. J Hepatol 2010, 52:605-613.
36. Reinglas J., Haddad H., Davies R.A., Mielniczuk L. Cardiorenal syndrome and heart failure. Curr Opin Cardiol 2010, 25:141-147.
37. Cianciulli P., Sorrentino F., Forte L., Palombi M., Papa G., Meloni C., et al. Acute renal failure occurring during intravenous desferrioxamine therapy: recovery after haemodialysis. Haematologica 1992, 77:514-515.
38. Li Volti S., Maccarone C., Li Volti G., Romeo M.A. Acute renal failure following deferoxamine overdose. Pediatr Nephrol 2003, 18:1078-1079.
39. Prasannan L., Flynn J.T., Levine J.E. Acute renal failure following deferoxamine overdose. Pediatr Nephrol 2003, 18:283-285.
40. Clajus C., Becker J.U., Stichtenoth D.O., Wortmann J., Schwarz A., Kielstein J.T. Acute kidney injury due to deferoxamine in a renal transplant patient. Nephrol Dial Transplant 2008, 23:1061-1064.
41. Hirschberg R., Bennett W., Scheinman J., Coppo R., Ponticelli C. Acute kidney injury due to deferoxamine in a renal transplant patient. Nephrol Dial Transplant 2008, 23:2704-2705. [author reply 5].
42. Brosnahan G., Gokden N., Swaminathan S. Acute interstitial nephritis due to deferasirox: a case report. Nephrol Dial Transplant 2008, 23:3356-3358.
43. Rafat C., Fakhouri F., Ribeil J.A., Delarue R., Le Quintrec M. Fanconi syndrome due to deferasirox. Am J Kidney Dis 2009, 54:931-934.
44. Even-Or E., Becker-Cohen R., Miskin H. Deferasirox treatment may be associated with reversible renal Fanconi syndrome. Am J Hematol 2010, 85:132-134.
45. Grange S., Bertrand D.M., Guerrot D., Eas F., Godin M. Acute renal failure and Fanconi syndrome due to deferasirox. Nephrol Dial Transplant 2010, 25:2376-2378.
46. Cappellini M.D., Cohen A., Piga A., Bejaoui M., Perrotta S., Agaoglu L., et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006, 107:3455-3462.
47. Cappellini M.D., Porter J., El-Beshlawy A., Li C.K., Seymour J.F., Elalfy M., et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010, 95:557-566.
48. Cappellini M.D., Taher A. Deferasirox (Exjade) for the treatment of iron overload. Acta Haematol 2009, 122:165-173.
49. Pusey C.D., Saltissi D., Bloodworth L., Rainford D.J., Christie J.L. Drug associated acute interstitial nephritis: clinical and pathological features and the response to high dose steroid therapy. Q J Med 1983, 52:194-211.
50. Vichinsky E., Onyekwere O., Porter J., Swerdlow P., Eckman J., Lane P., et al. A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease. Br J Haematol 2007, 136:501-508.
51. Taher A., Cappellini M.D., Vichinsky E., Galanello R., Piga A., Lawniczek T., et al. Efficacy and safety of deferasirox doses of >30mg/kg per d in patients with transfusion-dependent anaemia and iron overload. Br J Haematol 2009, 147:752-759.
52. Levi S., Rovida E. The role of iron in mitochondrial function. Biochim Biophys Acta 2009, 1790:629-636.
53. Schnermann J., Briggs J.P. Tubuloglomerular feedback: mechanistic insights from gene-manipulated mice. Kidney Int 2008, 74:418-426.
54. Abeysinghe R.D., Roberts P.J., Cooper C.E., MacLean K.H., Hider R.C., Porter J.B. The environment of the lipoxygenase iron binding site explored with novel hydroxypyridinone iron chelators. J Biol Chem 1996, 271:7965-7972.
55. Zambonelli C., Roberts M.F. An iron-dependent bacterial phospholipase D reminiscent of purple acid phosphatases. J Biol Chem 2003, 278:13706-13711.
56. Tanji K., Imaizumi T., Matsumiya T., Itaya H., Fujimoto K., Cui X., et al. Desferrioxamine, an iron chelator, upregulates cyclooxygenase-2 expression and prostaglandin production in a human macrophage cell line. Biochim Biophys Acta 2001, 1530:227-235.
57. Hisakawa N., Nishiya K., Tahara K., Matsumori A., Hashimoto K. Down regulation by iron of prostaglandin E2 production by human synovial fibroblasts. Ann Rheum Dis 1998, 57:742-746.
58. Huang X.P., Thiessen J.J., Spino M., Templeton D.M. Transport of iron chelators and chelates across MDCK cell monolayers: implications for iron excretion during chelation therapy. Int J Hematol 2010, 91:401-412.
59. Vichinsky E. Clinical application of deferasirox: practical patient management. Am J Hematol 2008, 83:398-402.